Integrated Filing — IndAS



General information about company

Scrip Code 544645
NSE Symbol PARKHOSPS
MSEI Symbol NOTLISTED
ISIN INE119201023
Name of company PARK MEDI WORLD LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 03-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 29-07-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Healthcare Services
Start date and time of board meeting 03-08-2026   08:00:00
End date and time of board meeting 03-08-2026   09:20:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
NA



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 3,353.20 3,353.20
Other income 466.80 466.80
Total income 3,820.00 3,820.00
2 Expenses
(a) Cost of materials consumed 541.90 541.90
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (7.10) (7.10)
(d) Employee benefit expense 875.40 875.40
(e) Finance costs 86.00 86.00
(f) Depreciation, depletion and amortisation expense 338.10 338.10
(f) Other Expenses
1 Professional and consultancy fees 517.70 517.70
2 Other Expenses 1,296.90 1,296.90
Total other expenses 1,814.60 1,814.60
Total expenses 3,648.90 3,648.90
3 Total profit before exceptional items and tax 171.10 171.10
4 Exceptional items 0.00 0.00
5 Total profit before tax 171.10 171.10
6 Tax expense
7 Current tax 34.40 34.40
8 Deferred tax 28.30 28.30
9 Total tax expenses 62.70 62.70
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 108.40 108.40
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 108.40 108.40
17 Other comprehensive income net of taxes (7.30) (7.30)
18 Total Comprehensive Income for the period 101.10 101.10
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 8,638.60 8,638.60
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.03 0.03
Diluted earnings (loss) per share from continuing operations 0.03 0.03
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.03 0.03
Diluted earnings (loss) per share from continuing and discontinued operations 0.03 0.03
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes to the unaudited standalone financial results for the quarter and year ended June 30, 2026 1. The unaudited standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) - 34 “Interim Financial Reporting” notified under Section 133 of the Companies Act, 2013 (“the Act”) read with the Companies (Indian Accounting Standard Rules), 2015 (as amended from time to time) and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended (Listing Regulations). 2. The unaudited standalone financial results (‘the Statement) of Park Medi World Limited (‘the company’) for the quarter ended June 30, 2026 were reviewed by the Audit committee on August 03, 2026 and approved by the Board of Directors at its meeting held on August 03, 2026 in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, and have been subjected to limited review by the statutory auditors of the company who have issued an unmodified opinion on the same. 3. The Company has launched a 350 bedded advanced multi-super specialty hospital at Panchkula on April 10, 2026. The Panchkula hospital is equipped with advanced diagnostics, modular operation theatres, critical care infrastructure, and will deliver comprehensive care across key specialties including oncology, neurosciences, orthopaedics, cardiology, and critical care including robotic-assisted procedures. 4. The Company has successfully acquired 80% shareholding of V3 Healthcare Private Limited on July 31, 2026 which operates a multi-super speciality Hospital in the name of “The Medicity Hospital - Rudrapur”, Uttaranchal having capacity of 330 beds. Remaining 20% will be acquired by April 30, 2030. Overall cost of acquisition is approx. Rs. 1,770 millions. Consequent to this acquisition, V3 Healthcare Private Limited has become a subsidiary of the Company. Further, the Hospital has been launched on August 2, 2026. 5. Umkal Healthcare Private Limited , the wholly owned subsidiary of the Company, has proposed the expansion of its existing 225-beded Park Hospital in Palam Vihar, Gurugram, with addition of 100 new beds. The newly expanded facility will be branded as Park Hospital Platinum and the proposed capacity addition is to be completed by November 2026. Overall cost of additional beds will be approx. Rs. 250 millions which is proposed to be funded from internal accruals. 6. Park Medicenters and Institutions Private Limited, a subsidiary of the Company, has incorporated a wholly owned subsidiary in the name of “Healplus Medical Services Private Limited” having CIN: U47721DC2026PTC471594, on May 20, 2026. The new subsidiary has not commenced business operations as of June 30, 2026, and hence has no financial impact on the consolidated results. 7. During the quarter ended June 30, 2026, the Company did not receive any investor complaint. No complaints were pending resolution as on June 30, 2026. The Company has adequate systems and processes in place to address investor grievances in a timely manner in compliance with Regulation 13 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015. 8. The utilisation of the IPO proceeds is summarised below: Object of the issue Utilisation planned Utilised upto Amount pending for utilisation as per prospectus: as per prospectus June 30, 2026 as on June 30, 2026 Repayment/ prepayment, in full or 3,800.00 3,800.00 - in part, of outstanding borrowings availed by our Company and our Subsidiaries Funding capital expenditure for 605.00 195.19 409.81 development of new hospital by our Subsidiary Park Medicity (NCR) Private Limited Funding capital expenditure for 274.59 36.08 238.51 purchase of medical equipment by our Company and our Subsidiaries, Blue Heavens Healthcare Private Limited and Ratangiri Innovations Private Limited Unidentified inorganic acquisitions 2,453.18 2,453.18 - and general corporate purposes Total 7,132.77 6,484.45 648.32 Issue expenses towards IPO 567.23 567.23 - Grand Total 7,700.00 7,051.68 648.32 There is no deviation in the utilization of proceeds from the objects stated in the offer document and there is no variation in the terms of contract referred to in the prospectus. 9. Previous period figures have been regrouped / reclassified wherever necessary to conform to current period classification and rounding off errors have been ignored. 10. The unaudited standalone financial results for the quarter ended June 30, 2026 are available on the Company's website at www.parkhospital.in and also on the website of BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com, where the shares of the Company are listed.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-06-2026 30-06-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of employee defined benefit plans (9.80) (9.80)
Total Amount of items that will not be reclassified to profit and loss (9.80)
2 Income tax relating to items that will not be reclassified to profit or loss (2.50) (2.50)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (7.30) (7.30)





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Agiwal and associates Yes 28-02-2029


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Public Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 17-12-2025
Amount Raised 77,000.00
Report filed for Quarter ended 30-06-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable Crisil Rating Limited
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review
Comments of the auditors, if any
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Repayment/ prepayment, in full or in part, of outstanding borrowings availed by our Company and our Subsidiaries 0 38,000.00 0.00 38,000.00 0.00
2 Funding capital expenditure for development of new hospital by our Subsidiary Park Medicity (NCR) Private Limited 0 6,050.00 0.00 1,951.90 0.00
3 Funding capital expenditure for purchase of medical equipment by our Company and our Subsidiaries, Blue Heavens Healthcare Private Limited and Ratangiri Innovations Private Limited 0 2,745.90 0.00 360.80 0.00
4 Unidentified inorganic acquisitions and general corporate purposes 0 24,531.80 0.00 24,531.80 0.00


Signatory Details

Name of signatory Sanjay Sharma
Designation of person Director
Place Gurugram
Date 03-08-2026